Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $94.20 Average Target Price from Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been assigned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $94.20.

A number of research firms recently commented on PBH. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson boosted their target price on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Congress Asset Management Co. MA raised its stake in shares of Prestige Consumer Healthcare by 596.2% during the 4th quarter. Congress Asset Management Co. MA now owns 679,256 shares of the company’s stock valued at $41,584,000 after buying an additional 581,685 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Prestige Consumer Healthcare by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,756,138 shares of the company’s stock valued at $352,391,000 after buying an additional 63,375 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at about $320,000. Congress Wealth Management LLC DE raised its stake in shares of Prestige Consumer Healthcare by 8.8% during the 1st quarter. Congress Wealth Management LLC DE now owns 124,281 shares of the company’s stock valued at $9,018,000 after buying an additional 10,061 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Prestige Consumer Healthcare by 0.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,047,352 shares of the company’s stock valued at $75,996,000 after acquiring an additional 4,278 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Up 1.7 %

Shares of NYSE:PBH opened at $71.25 on Friday. The stock has a fifty day simple moving average of $71.03 and a two-hundred day simple moving average of $69.24. The stock has a market capitalization of $3.54 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 1.93 and a beta of 0.47. Prestige Consumer Healthcare has a 12-month low of $56.61 and a 12-month high of $75.80. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.04. The firm had revenue of $267.10 million during the quarter, compared to analysts’ expectations of $260.54 million. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The company’s revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.06 earnings per share. On average, research analysts anticipate that Prestige Consumer Healthcare will post 4.43 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.